Default company panoramic image

Modulation Therapeutics Incoporated

Modulation Therapeutics is developing a novel, first in class drug for multiple myeloma and other cancers that metastasize to bone.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Tampa, FL, USA
  • Currency USD
  • Founded June 2011
  • Employees 2
  • Website

Company Summary

The company is developing a novel first in class peptide mimetic drug called MT-101 for multiple myeloma and other cancers that metastasize to bone. MT-101 has a novel mechanism of action that differentiates it from all other existing drugs for myeloma. Preclinical data show promising single agent and combination (Velcade) efficacy with no overt toxicity in vivo. We seek investors to fund development of MT-101 from IND through Phase I/IIa.


  • Default avatar
    Mark L McLaughlin
    Executive Vice President

  • Default avatar
    Lori Hazlehurst

  • Default avatar
    Michael Cerio
    Interim CEO

    Michael Cerio, MBA, MS is interim CEO of Modulation Therapeutics. Previously he was Senior Director of Business Development for Genzyme Corporation and led licensing and M&A for the Genzyme Genetics business unit. He previously led business development activities for BG Medicine and Genaissance Pharmaceuticals. He received his MBA from Columbia University School of Business and an MS in Molecular Biology from University of Connecticut.


  • Default avatar
    John Igoe, Edwards Wildman Palmer, LLP; 525 Okeechobee Boulevard, Suite 1600; West Palm Beach, Florida 33401
    Default avatar
    Carr, Riggs & Ingram, LLC; 2111 Drew Street; Clearwater, FL 33765

Previous Investors

  • Default avatar
    Multiple Myeloma Research Foundation